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Abstract: Enhanced recovery after surgery (ERAS) pathways are
multimodal, evidence-based approaches to optimize patient outcome
after surgery. However, the use of ERAS protocols to improve morbidity
and recovery time without compromising safety following pancreatico-
duodenectomy (PD) remains to be elucidated.
We conducted a systemic review and meta-analysis to assess the
safety and efficacy of ERAS protocols compared with conventional
perioperative care (CPC) in patients following PD.
PubMed, Medline, Embase, and Science Citation Index Expanded
and Cochrane Central Register of Controlled Trials (CENTRAL) in The
Cochrane Library were searched between January 2000 and June 2015.
The patients who underwent PD with ERAS protocols or CPC werenes, PhD, Qing Xi g Hu, MD,
PhD, and Michael G. Raraty, PhD, FRCS
A meta-analysis, meta-regression, sensitivity analysis, and subgroup
analysis were performed to estimate the postoperative outcomes between
the 2 groups and identified the potential confounders. We used the
methodological index for nonrandomized studies checklist to assess
methodological qualities. Weighted mean differences (WMD) or odds
ratios (OR) were calculated with their corresponding 95% confidence
intervals (CI). The publication bias tests were also performed through the
funnel plots.
In total, 14 nonrandomized comparative studies with 1409 ERAS
cases and 1310 controls were analyzed. Implementation of an ERAS
protocol significantly reduced PLOS (WMD: 4.17 days; 95%CI:
5.72 to 2.61), delayed gastric emptying (OR: 0.56; 95%CI: 0.44–
0.71), overall morbidity (OR: 0.63; 95% CI: 0.54–0.74), and in-
hospital costs compared to CPC (all P< 0.001). There were no
statistically significant differences in other postoperative outcomes.
Age, gender, and ERAS component implementation did not signifi-
cantly contribute to heterogeneity for PLOS as shown by meta-
regression analysis.
Our study suggested that ERAS was as safe as CPC and im-
proved recovery of patients undergoing PD, thus reducing in-hospital
costs. General adoption of ERAS protocols during PD should be
recommended.
(Medicine 95(18):e3497)
Abbreviations: CI = confidence interval, CPC = conventional
perioperative care, DGE = delayed gastric emptying, ERAS =
enhanced recovery after surgery, ISGPF = International Study Group
of Pancreatic Fistula, ISGPS = International Study Group of Pancreatic
Surgery, OR = odds ratios, PD = pancreaticoduodenectomy, PLOS =
postoperative length of hospital stay, POPF = postoperative pancreatic
fistula, PPPD = pylorus-preserving pancreaticoduodenectomy.
INTRODUCTION
H igh standards of perioperative management in conjunctionwith expert surgery are the corner stones of postoperative
recovery. A formalized enhanced recovery after surgery
(ERAS) program was first implemented in elective colorectal
surgery.1 ERAS involves a multidisciplinary team approach and
thoughtful review of all aspects of operative and perioperative
care, such as optimal pain control (including regional anesthe-
sia), minimally invasive techniques, and aggressive postopera-
tive rehabilitation (including nutritional support and
ambulation).2,3 It has been further developed for joint,4 breast,5
and colorectal6 surgeries, consistently demonstrating signifi-
cantly accelerated postoperative recovery and shortened post-spital stay (PLOS), as well as reduced
le maintaining similar safety profiles
tional perioperative care (CPC) alone.7
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As a result, there is a consensus agreement that ERAS should be
a standard practice in elective colorectal surgery.8
Guidelines published by the ERAS group also recommend
its use in pancreaticoduodenectomy (PD); however, this recom-
mendation was based on a very limited number of studies.9 A
subsequent meta-analysis7 was only able to include 4 studies
and found that ERAS reduced overall morbidity without affect-
ing readmission rates or mortality.10–13 The effect of ERAS on
PLOS and in-hospital costs after PD remains unexplored. This
systematic review and meta-analysis incorporates the most
recent published literature on this topic and aims to evaluate
the effects of implementing an ERAS program following PD.
METHODS
Data Sources and Search Strategy
Major public medical and scientific databases including
Medline, Embase, and Science Citation Index Expanded and
Cochrane Central Register of Controlled Trials (CENTRAL) in
The Cochrane Library were searched for studies published in
the English language comparing ERAS with CPC after PD,
from January 2000 to June 2015. The following search terms
were used, in all possible combinations: ‘‘Whipple,’’ ‘‘pancrea-
ticoduodenectomy,’’ ‘‘pancreatoduodenectomy,’’ ‘‘pancreato-
duodenal resection,’’ ‘‘ERAS program,’’ ‘‘enhanced
recovery,’’ ‘‘fast track,’’ ‘‘critical pathway,’’ and ‘‘clinical path-
way.’’ Reference lists of selected articles were further examined
for relevant articles during the initial search. Only comparative
clinical trials with full-text descriptions were included. Final
inclusion of articles was determined by consensus of 3 authors.
The reporting of this systematic review is conducted in accord-
ance with the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement.14
Inclusion and Exclusion Criteria
Inclusion criteria were: articles published in English in
peer-reviewed journals; human studies; studies reporting at least
one outcome of interest as defined below; and where multiple
studies by the same institute and/or authors had overlapping
enrollment times, only the higher quality study was included in
the analysis.
Exclusion criteria were: abstracts, letters, editorials, reviews
or guidelines, and case reports; noncomparative studies; and
studies including patients undergoing procedures other than PD.
Outcomes of Interest
The primary outcome was PLOS. The secondary outcomes
were rates of postoperative pancreatic fistula (POPF), delayed
gastric emptying (DGE), overall morbidity, readmission, reo-
peration, mortality, and in-hospital costs.
PLOS was defined as the postoperative time interval in
days. POPF was defined as per the International Study Group of
Pancreatic Fistula (ISGPF) definition15 or as defined by the
study’s authors in studies conducted prior to 2005. DGE was
defined according to the International Study Group of Pancrea-
tic Surgery (ISGPS) definition16 or author’s own definitions.
Overall morbidity was defined as all complications from oper-
ation to discharge or within 30 days. Readmissions were defined
as any hospital admission for any reason within 30 days of
discharge. Reoperation was defined as the need for laparotomy
Xiong et alas a consequence of the 1st operation within 30 days. Mortality
was defined as death from any cause prior to discharge from
hospital or within 30 days.
2 | www.md-journal.comData Extraction and Quality Assessment
Data were extracted by 2 independent observers using
standardized forms. The recorded data included characteristics
of included study, baseline parameters of patients, inclusion
criteria for ERAS, elements of ERAS protocol, postoperative
outcomes, and in-hospital costs. Means and standard deviations
of the outcomes were used for meta-analysis unless otherwise
mentioned. Methodologies for estimating means and standard
deviations from medians and ranges have been described pre-
viously.17,18 The quality of included studies was assessed using
the Methodological Index for Non-Randomized Studies
(MINORS) checklist.19 This instrument scores 8 methodologi-
cal items for noncomparative studies and an additional 4 criteria
for comparative studies. The items are scored 0 (not reported), 1
(reported but inadequate), or 2 (reported and adequate). The
global ideal scores were 16 for noncomparative studies and 24
for comparative studies.
Statistical Analysis
Meta-analysis was conducted by using Review Manager
Version 5.3 software (Version 5.3 for Windows, The Cochrane
Collaboration, 2014). Continuous and categorical variables
were calculated as weighted mean differences or odds ratios
(ORs) with their corresponding 95% confidence interval (CI),
respectively. Heterogeneity was assessed using a Chi-square
test, where P< 0.1 was considered significant. I2 values were
used for the evaluation of statistical heterogeneity; an I2 value of
50% or more indicated the presence of heterogeneity.20 The
fixed-effects analysis21 was initially used for all outcomes,
while the random-effects model22 was calculated when hom-
ogeneity of studies was not supported by the test. Data other-
wise unsuitable for meta-analysis were described in the text.
Subgroup and sensitivity analyses were carried out by
excluding each study out of each outcome measure. Subgroup
analyses were performed by separately analyzing only high
quality studies (MINORS score 13), studies conducted in
Western or Eastern countries, and studies in which n> 100.
Sensitivity analyses were conducted to evaluate effects of
operative technique (PD or PD with pylorus-preserving pan-
creatoduodectomy [PPPD]), pancreatic texture, or matching
preoperative nutritional status. Meta-regression was carried
out to assess the impact of age, gender, and implementation
of ERAS elements (not used in >2 studies) on heterogeneity
using Stata SE Version 13 Software (Stata Corp LP, TX) with a
P< 0.05 considered significant. Funnel plots23 were con-
structed to evaluate potential publication bias based on the
PLOS, readmission, and other secondary outcomes.
Ethics, Standards of Reporting, Data Availability
This systematic review was not submitted to any biome-
dicalethical committee for approval, and no additional consent
was sought from individuals analyzed. It was performed and
reported according to the PRISMA standard. All primary out-
come data are fully available from the published papers. Other
data are partially available and are pointed out in the tables.
RESULTS
Description of Trials Included in the
Medicine  Volume 95, Number 18, May 2016Meta-analysis
The search strategy initially generated 436 relevant clinical
trials. No randomized clinical trials were identified. Figure 1
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PRISMA statement for meta-analyses.
Application of inclusion/exclusion criteria led to
17 articles10–13,24–36 being subjected to detailed analysis.
Of these studies, a further three10,32,33 were excluded as
they included pancreatic resections other than PD, leaving 14
studies11–13,24–31,34–36 for data extraction. Patients in Sutcliff
et al’s study34 were divided into high- and low-risk according to
FIGURE 1. Preferred Reporting Items for Systematic Reviews an
identification and inclusion of selected studies.sion, persistent vomiting or vomiting occurring after the 10ththe risk of POPF using drain fluid amylase. As only low-risk
patients were selected for all other ERAS programs, we
included the patients at low-risk of POPF for analysis.
Characteristics and Quality Assessment of
Included Studies
Detailed study characteristics and quality assessments are
shown in Table 1. All the included studies were retrospective
case–control series. Eleven studies11–13,24–27,30,34–36 were con-
ducted inWestern populations, and 8 studies11–13,26–28,30,31 had
sample sizes >100. A total of 2719 patients were included with
1409 and 1310 patients in the ERAS group and CPC group,
respectively. There were 12 studies11–13,24–26,28,29,31,34–36 with
MINORS scores 13.
Baseline Parameters of Patients and Inclusion
Criteria for SurgeryThe baseline parameters and inclusion criteria for ERAS
are shown in Table 2. The mean or median age ranged from 44.2
to 70. The gender, body mass index, American Society of
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Anesthesiologist score, pancreatic texture, and duct status
distribution were equal for ERAS and CPC groups in most
of the studies. Malignant pancreatic diseases accounted for 50%
to 95% of the indications for surgery. Patients with benign
pancreatic tumor, chronic pancreatitis, and other pancreatic
disorders were also included for surgery.
In 6 studies11,24,29,30,35,36 only PD was performed, while
PPPD was used as well as PD in 8 studies.12,13,25–28,31,34 One
Japanese study28 included both PPPD and subtotal stomach-
preserving PD alongside PD. Eleven studies13,24,26–31,34–36
used the ISGPF definition for POPF. Kennedy et al11 defined
POPF as drainage of>30mL with serum amylase level>3-fold
for more than 10 days after surgery, while the diagnostic criteria
were not described in the remaining 2 studies.12,25 Eight
studies7,24,28–31,35,36 defined DGE as per ISGPS guidance, 3
studies11,13,26 defined it as a need for nasogastric decompres-
eta-Analyses (PRISMA) flow diagram depicting the process ofpostoperative day, and the remaining 3 studies12,25,34 did not
state their criteria.
Essential ERAS Elements Used in Included Studies
Individual elements of different ERAS protocols used in
each study are listed in Table 3. Although there were significant
differences in the use of prophylactic antibiotics and octreotide,
most studies used epidural and/or patient-controlled analgesia,
prokinetic agents, and goal-directed mobilization and had pre-
defined criteria for removal of drains, nasogastric tubes, and
catheters as well as a preagreed discharge plan. Early oral intake
was encouraged in most of studies.
www.md-journal.com | 3
study of Williamsson et al,36 with costs of s10400 (6519–
TABLE 1. Study Characteristics and Quality Assessment
Authors Year Country Study Design Group No. of Patients MINORS Score
Kennedy et al11 2007 USA Case–control ERAS 91 16/24
CPC 44
Vanounou et al12 2007 USA Case–control ERAS 145 15/24
CPC 64
Balzano et al13 2008 Italy Case–control ERAS 252 13/24
CPC 252
Abu Hilal et al24 2013 UK Case–control ERAS 20 15/24
CPC 24
Nikfarjam et al25 2013 Australia Case–control ERAS 20 13/24
CPC 21
Braga et al26 2014 Italy Case–control ERAS 115 17/24
CPC 115
Coolsen et al27 2014 The Netherlands Case–control ERAS 86 12/24
CPC 97
Kobayashi et al28 2014 Japan Case–control ERAS 100 13/24
CPC 90
Pillai et al29 2014 India Case–control ERAS 20 17/24
CPC 20
Nussbaum et al30 2015 USA Case–control ERAS 100 11/24
CPC 142
Shao et al31 2015 China Case–control ERAS 325 15/24
CPC 310
Sutcliffe et al34 2015 UK Case–control ERAS 44 15/24
CPC 37
Morales Soriano et al35 2015 Sweden Case–control ERAS 50 17/24
CPC 50
Williamsson et al36 2015 Spain Case–control ERAS 41 17/24
CPC 44
CPC¼ conventional perioperative care, ERAS¼ enhanced recovery after surgery, MINORS¼Methodological Index for Non-Randomized
Xiong et al Medicine  Volume 95, Number 18, May 2016Meta-Analysis Outcomes
The postoperative outcomes are detailed in Supplementary
Table 1, http://links.lww.com/MD/A928 and meta-analysis
results are shown in Figures 2 and 3.
Primary Outcome
All studies reported the primary outcome: PLOS. Meta-
analysis including 2719 patients showed that patients in the
ERAS group had a shorter PLOS compared with those in the
CPC group (weighted mean differences: 4.17 days; 95%CI:
5.72 to 2.61, P< 0.00001; Figure 2), although a moderate
degree of heterogeneity was observed (I2¼ 57%, P¼ 0.008).
Secondary Outcomes
The rates of POPF in all studies (OR: 0.88, 95%CI: 0.73–
1.08; P¼ 0.22; Figure 3A) or only those using the ISGPF
definition (OR: 0.90, 95%CI: 0.74–1.10; P¼ 0.30) were similar
between ERAS and CPC groups. Furthermore, there was no
significant difference in POPF B/C (OR: 0.87, 95%CI: 0.66–
1.14; P¼ 0.32) between ERAS and CPC groups.
Compared to CPC, the incidence of DGE (OR: 0.56; 95%
CI: 0.44–0.71, P< 0.0001; Figure 3B) was lower in the ERAS
Studies.group. This difference remained statistically significant when
only including studies adhering to the ISGPS definition (OR:
0.57, 95%CI: 0.42–0.77; P¼ 0.003).
4 | www.md-journal.comThe incidence of overall morbidity (OR: 0.63; 95%CI:
0.54–0.74, P< 0.00001; Figure 3C) was lower in the
ERAS group.
There were no statistically significant differences in rates
of readmission (OR: 1.05, 95%CI: 0.82–1.34; P¼ 0.71;
Figure 3D), reoperation (OR: 0.86, 95%CI: 0.60–1.22;
P¼ 0.39; Figure 3E), or mortality (OR: 0.95, 95%CI: 0.55–
1.64; P¼ 0.86; Figure 3F).
In-hospital costs were reported by 4 studies11,12,31,36 and
showed that ERAS protocols significantly reduced costs. Ken-
nedy et al11 reported that the respective average costs were US
$126,566 4883 in the ERAS group and $240,242 32,490 in
the CPC group (P< 0.0001). Vanounou et al12 reported
decreased costs when using an ERAS protocol (a reduction
from $28,886 to $23,344 following ERAS implementation).
Shao et al31 also reported a reduction of costs from
RMB 68,663.18 26,639.74 to RMB 58,505.19 34,044.92
(P< 0.001). These findings again were corroborated in the39558) ands14576 (8245–42750) in the ERAS group and CPC
group (P< 0.001), respectively.Subgroup, Sensitivity, and Meta-Regression Analyses
The results of the subgroup analysis are summarized in
Table 4. The results of sensitivity analysis and meta-regression
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 3. Frequency of Elements Included in Enhanced
Recovery After Surgery (ERAS) Protocols for Pancreaticoduo-
denectomy
Element Frequency
Prophylactic antibiotics 7/1411–12,25,27,30,35,36
Octreotide 3/1427,34,36
Removal of drains 13/1411–13,24–30,34–36
Epidural or patient-controlled
analgesia
11/1411,13,24,26–27,29–31,34–36
Foley catheters 10/1411–12,25,27–31,34,36
Prokinetic agents 8/1424–30,35
Nasogastric tubes 13/1411–13,25–31,34–36
11–13,25–31,34–36
Xiong et alanalysis are also summarized Supplementary Tables 2 and 3,
http://links.lww.com/MD/A928, respectively.
The subgroup analysis including only high quality studies
yielded similar results to the primary analysis. When analyzing
only studies conducted in Western countries, the results were
also the same, but with abolished heterogeneity for PLOS
(I2¼ 0%); expectedly, there was increased heterogeneity in
studies conducted in Eastern countries (I2¼ 86%), and further-
more, the reduction of overall morbidity by ERAS was also no
longer statistically significant (P¼ 0.1). The heterogeneity for
PLOS in larger studies (n> 100) was increased (77%) with
consistent clinical outcomes when compared to the primary
analysis. In the sensitivity analysis, studies reporting matching
preoperative nutritional status, pancreatic texture, or type of
procedure (PD, PD/PPPD) showed reduced heterogeneity for
PLOS and a consistent reduction of PLOS by ERAS. Age,
Early oral intake 13/14
Goal-directed mobilization 12/1411–13,25–27,29–31,34–36
Discharge planning 11/1411,25–31,34–36gender, and ERAS component implementation did not signifi-
cantly contribute to heterogeneity for PLOS as shown by meta-
regression analysis.
Study or Subgroup
Kennedy 2007
Vanounou 2007
Balzano 2008
Nikfarjam 2013
Abu Hilal 2013
Braga 2014
Coolsen 2014
Pillai 2014
Kobayashi 2014
Shao 2015
Sutcliffe 2015
Nussbaum 2015
Williamsson 2015
Morales Soriano 2015
Total (95% CI)
Heterogeneity: Tau² = 3.28; Chi² = 25.34, df = 11 (P = 0.008); I² = 57%
Test for overall effect: Z = 5.25 (P < 0.00001)
Mean
7
8
13
9.75
9.25
14.6
13
15.75
21.9
13.94
7
11
10
14.2
SD
0
0
29.25
5.75
5
9.8
17.75
8.75
11.9
7.45
12.75
6.45
10.25
9.19
Total
91
145
252
20
20
115
86
20
100
325
44
100
50
41
1409
Mean
13
8
15
16.25
14.25
16.1
20
22
36.3
17.6
9
13
14
18.7
SD
0
0
27.25
9.25
7.75
8.9
35.25
12.75
23.8
7.71
16.5
7.08
12.75
13.44
Total
44
64
252
21
24
115
97
20
90
310
37
142
50
44
1310
Weigh
6.6%
7.0%
9.0%
13.1%
3.2%
4.1%
5.7%
17.3%
4.4%
15.6%
7.3%
6.7%
100.0%
ERAS CPC
FIGURE 2. Forest plots demonstrating the primary outcome postop
pancreaticoduodenectomy. Pooled WMDs with 95% CIs were calcu
CPC¼ conventional perioperative care, ERAS¼ enhanced recovery aft
6 | www.md-journal.comPublication Bias
The funnel plots based on PLOS and readmission are
shown in Supplementary Figure 1, http://links.lww.com/MD/
A928. There was no evidence of publication bias of PLOS,
readmission, and the other secondary outcomes (data not
shown).
DISCUSSION
The 1-stage PD, or Whipple procedure, remains one of the
most technically challenging general surgical operations with
extreme impact on patient physiology.37 Nowadays, despite
reductions in mortality of this procedure to around 5% in high-
volume specialized centers,38 it is still associated with post-
operative morbidity up to 60%.38–40 A previous systematic
review41 and meta-analysis7 suggest that using an ERAS pro-
tocol in pancreatic resections may help to shorten PLOS and
reduced overall morbidity without affecting readmission rates
or mortality. When only focusing on PD, a reduction of overall
morbidity was noticed without significant differences in rates of
readmission and mortality by the implementation of ERAS.7
The PLOS and in-hospital costs, however, were not specifically
analyzed.7,41 We included 14 studies in our meta-analysis,
demonstrating that implementation of ERAS program following
PD can reduce PLOS, DGE, overall morbidity and in-hospital
costs without affecting POPF, reoperation, readmission, and
mortality rates. The primary outcome and most of the secondary
outcomes remained unchanged in the subgroup and sensitivity
analyses.
A large number of factors contribute to the timing of
discharge of a patient following major surgery relating both
to patient recovery and the healthcare environment. Patient
morbidity may significantly contribute to PLOS; however,
patient baseline characteristics and inclusion criteria for surgery
were over all well balanced in the ERAS and CPC groups,
Medicine  Volume 95, Number 18, May 2016indicating ERAS implementation as the main factor affecting
PLOS. From a patient perspective, the reduction in PLOS is
associated with reduced DGE rates and earlier return to normal
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Study or Subgroup
Kennedy 2007
Balzano 2008
Abu Hilal 2013
Braga 2014
Kobayashi 2014
Pillai 2014
Coolsen 2014
Williamsson 2015
Nussbaum 2015
Morales Soriano 2015
Shao 2015
Sutcliffe 2015
Total (95% CI)
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quicker return to preoperative levels of mobility resulting in an
overall improvement in the postoperative experience. Although
FIGURE 3. Forest plots demonstrating secondary outcomes in te
operative pancreatic fistula; (B) delayed gastric emptying; (C) o
mortality. CPC¼ conventional perioperative care, ERAS¼ enhancepain and mobility levels were not specifically reported by all
individual studies, they were included in the measure of overall
morbidity, a reduction of which was seen in the ERAS group in
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.this analysis. Factors relating to the healthcare environment can
also delay discharge and, amongst others, these include avail-
ability of community support and transportation.42 Healthcare
s of ERAS versus CPC after pancreaticoduodenectomy. (A) Post-
ll morbidity; (D) readmission rate; (E) reoperation rate; and (F)
covery after surgery.systems also function in entirely different cultural and econ-
omical environments. In the UK, it is common practice to
discharge patients from hospital early and continue care in
www.md-journal.com | 7
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Xiong et al Medicine  Volume 95, Number 18, May 2016the community if required through the use of specialist com-
munity nursing and therapy staff. In countries including China
and India, not all patients have medical insurance or are able to
fund convalescent periods in hospital, contributing to a higher
heterogeneity observed in our analysis which was reduced when
analyzing only studies from Western centers.
There is substantial and ever increasing evidence for
optimal practice relating to individual components of operative
and perioperative management, both specific to pancreatic
resections and surgery in general. The ERAS programs utilize
these data to plan idealized care, limiting variability of outcome
while maintaining patient-specific and individualized manage-
ment through the use of treatment protocols, targets/objectives
for staff and patients as well as embedding early warning
systems to identify problems. Indeed, members of local multi-
disciplinary teams often receive specific training relating to
ERAS components following its introduction, and this may in
part explain the identified patient benefits. It is self-evident,
therefore, that each specialist unit included in this meta-analysis
has developed and implemented their own individual ERAS
protocol, which differs slightly in details (e.g., how early the
drain or Foley was removed) to that of all others. This is also a
likely source for the observed heterogeneity seen in this meta-
analysis. Finally, there was heterogeneity in the definitions of
the outcome measures. For addressing this issue, we performed
a meta-regression analysis to assess the impact of ERAS
elements on heterogeneity for PLOS and found that none of
the parameters contributed significantly to heterogeneity.
ERAS pathways have previously been shown to reduce
FIGURE 3. (Continued)healthcare costs in a number of surgical procedures, including
pancreatic surgery.5,11,43 PLOS correlates with costs,44 so it was
not surprizing that in the 4 studies reported this outcome there
8 | www.md-journal.comwas a reduction of in-hospital costs in each center, resulting in
overall reduction in in-hospital costs in the EARS group in our
meta-analysis. There was a 10-fold difference between the
costliest and the cheapest center, with the greatest reductions
reported by the centers with the highest costs. Naturally, clinical
pathways require resources to develop, implement and main-
tain,45 but this cost will be offset somewhat by savings gener-
ated by the protocols. Nevertheless, the emphasis when
developing a service clearly has to remain with improving
patient care, and the reductions in morbidity reported in this
meta-analysis supports implementation of ERAS protocols
following PD on those grounds.
We base our analysis on best, currently available evidence,
consisting exclusively of retrospective studies. Clearly, blinded
implementation of such an ERAS protocol is impossible, and
simultaneous prospective cohorts of patients impractical, which
is why only retrospective cohorts have been published to date.
Therefore, to a certain extent, selection bias may affect the
results of the study. Prospective study designs such as cross-
over trials or use of national and international prospective
databases are of course possible, and also allow detailed evalu-
ation of individual elements within protocols.46 However, one
could argue that it is not necessary to trial a protocol that simply
implements a summation of best available evidence into daily
practice. As such, we conclude that implementation of a locally
agreed, standardized perioperative protocol designed and
implemented in the spirit of ERAS can enhance recovery in
patients undergoing PD.
In summary, the present study shows that ERAS protocols
reduced PLOS, DGE and overall morbidity without adversely
affecting rates of POPF, readmission, reoperation, or mortality
during PD, thereby reducing healthcare costs. Following ERAS
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Results of Subgroup Analysis
Outcome of Interest
No. of
Studies
No. of
Patients
OR/
WMD
95%
CI
P
Value
Heterogeneity
P Value I2, %
MINORS score 13
Primary outcome
Postoperative length of hospital stay 12 2294 4.54 6.38, 2.69 <0.00001 0.01 57
Secondary outcomes
Postoperative pancreatic fistula 10 2044 0.81 0.65, 1.01 0.06 0.24 22
Delayed gastric emptying 10 2044 0.47 0.36, 0.61 <0.00001 0.77 0
Overall morbidity 11 2253 0.60 0.51, 0.71 <0.00001 0.33 12
Readmission 12 2294 1.01 0.75, 1.35 0.96 0.75 0
Reoperation 6 1112 0.96 0.63, 1.48 0.86 0.81 0
Mortality 10 1718 1.12 0.60, 2.11 0.72 0.82 0
Studies in Western countries
Primary outcome
Postoperative length of hospital stay 11 1854 2.77 3.89, 1.64 <0.00001 0.48 0
Secondary outcomes
Postoperative pancreatic fistula 9 1604 0.98 0.77, 1.25 0.90 0.73 0
Delayed gastric emptying 9 1604 0.65 0.49, 0.87 0.003 0.25 22
Overall morbidity 9 1571 0.70 0.57, 0.86 0.0007 0.47 0
Readmission 11 1854 1.11 0.82, 1.50 0.49 0.72 0
Reoperation 7 1497 0.83 0.58, 1.18 0.30 0.92 0
Mortality 10 1913 0.95 0.54, 1.68 0.86 0.78 0
Studies in Eastern countries
Primary outcome
Postoperative length of hospital stay 3 865 7.83 14.75, 0.91 0.03 0.0007 86
Secondary outcomes
Postoperative pancreatic fistula 3 865 0.63 0.26, 1.54 0.31 0.02 74
Delayed gastric emptying 3 865 0.40 0.26, 0.62 <0.0001 0.23 31
Overall morbidity 3 865 0.60 0.33, 1.11 0.10 0.06 64
Readmission 3 865 0.92 0.59, 1.43 0.71 0.98 0
Mortality 2 230 0.96 0.16, 5.70 0.96 0.34 0
Studies with cases >100
Primary outcome
Postoperative length of hospital stay 8 2328 4.02 6.37, 1.66 0.0008 0.0006 77
Secondary outcomes
Postoperative pancreatic fistula 7 2119 0.82 0.57, 1.17 0.28 0.03 57
Delayed gastric emptying 7 2119 0.67 0.44, 1.02 0.06 0.06 50
Overall morbidity 7 2086 0.63 0.53, 0.75 <0.00001 0.18 32
Readmission 8 2328 1.08 0.83, 1.41 0.56 0.98 0
Reoperation 5 1368 0.83 0.57, 1.21 0.33 0.85 0
Mortality 7 1793 0.91 0.50, 1.64 0.75 0.86 0
e in
Medicine  Volume 95, Number 18, May 2016 Enhanced Recovery After Surgery Program During PDimplementation, data should be collected and published, pre-
ferably through the use of national or international databases,
allowing future analysis of the relative contributions of indi-
vidual protocol components.
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